92 results about "Peptide analog" patented technology

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The invention belongs to the technical field of biochemistry, and particularly relates to a DR8 cyclic peptide analogue and application thereof. The structure of the DR8 cyclopeptide analogue is R1-dAsp-His-Asn-Cys-Pro-Gln-dAla-Cys-CONH2, in the structural formula, R1 is a chain alkyl group with 1 to 30 carbon atoms, and a fourth amino acid and an eighth amino acid are subjected to cyclization through the chain alkyl group. The biological activity of the DR8 cyclic peptide analogue is researched, and an in-vitro cell model and an in-vivo animal model of renal fibrosis are constructed to evaluate indexes such as in-vitro anti-fibrosis activity, inhibition effect and in-vivo treatment effect of the DR8 cyclic peptide analogue. And the cytotoxicity, serum stability and pharmacokinetics of the DR8 cyclopeptide analogue are researched. Results show that compared with the polypeptide DR3penA, the DR8 cyclic peptide analogue obtained by the invention has better activity indexes and stability in all aspects, and can be used for preparing medicines for preventing renal fibrosis diseases.

The invention provides a human amylin polypeptide analogue containing non-natural amino acid and a derivative of the human amylin polypeptide analogue. According to the present invention, the human amylin polypeptide derivative obtained by introducing the non-natural amino acid to the N-terminal of the human amylin and modifying with the albumin binding residue can effectively prevent enzymatic degradation and prolong the half-life period, and has characteristics of improved solubility and / or physical stability and / or bioavailability and / or pharmacokinetic properties, the compound can be used for treating obesity and obesity-related diseases.

The present invention relates to a WKYMVm peptide analog comprising an amino acid sequence of Trp (W)-Lys (K)-Tyr (Y)-Met (M)-Val (V)-D-Met (m), in which at least one amino acid residue selected from the group consisting of Lys (K), Tyr (Y), and Met (M) in the amino acid sequence is substituted with a β3-amino acid residue or a peptoid residue, and a use thereof. The WKYMVm peptide analogs of the present invention has effects of increasing stability by increasing in vivo degradation half-life and of promoting activation of innate immune responses by neutrophils through activation of formyl peptide receptors, and thus can be effectively used in preventing or treating a disease that is be prevented or treated by formyl peptide receptors, especially an infectious disease or inflammatory disease.

The present invention provides synthetic peptide compounds and uses thereof for therapy and diagnostics of complement-mediated diseases, such as inflammatory diseases, autoimmune diseases, and microbial and bacterial infections; and non-complement-mediated diseases, such cystic fibrosis and various acute diseases. The invention is directed to modifications of a synthetic peptide of 15 amino acids from the Polar Assortant (PA) peptide, which is a scrambled peptide derived from human Astrovirus protein. In some embodiments, the invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of PA (e.g., sarcosine derivatives) having, for example, internal peptide substitutions, and modifications, including PEGylation at the N-terminus and C-terminus. The invention further provides methods of selecting at least one synthetic peptide for treating various conditions.

The present invention provides peptide compounds that regulate the complement system and methods of using these compounds. The invention is an isolated, purified peptide of 30 amino acids derived from human astrovirus protein, called CP1. The invention is directed to peptide compounds that are peptide mimetics, peptide analogs and / or synthetic derivatives of CP1 having, for example, internal peptide deletions and substitutions, deletions and substitutions at the N-terminus and C-terminus, and that are able to regulate complement activation. The invention further provides pharmaceutical compositions of therapeutically effective amounts of the peptide compounds and a pharmaceutically acceptable carrier, diluent, or excipient for treating a disease or condition associated with complement-mediated tissue damage.

The present disclosure encompasses pharmaceutical compositions or formulations of hepcidin peptide analogues or mimetics, as well as to the use of the formulations in the treatment and / or prevention of a variety of diseases, conditions, or disorders, including the treatment and / or prevention of iron overload diseases including hereditary hemochromatosis, iron-loading anemias, and other conditions and disorders described herein.

Provided herein are compounds that inhibit a binding interaction between a β integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.

The invention relates to a biological preparation prepared from astragalus polysaccharide and application of the biological preparation. The biological preparation comprises the following components: traditional Chinese medicine components: 15-20g of an astragalus-codonopsis pilosula-lucid ganoderma co-extract, 10-15g of an astragalus-atractylodes macrocephala-Chinese yam co-extract, 8-12g of an astragalus-medlar-dendrobe co-extract, 6-10g of an astragalus-ginseng-polygala tenuifolia co-extract and 5-8g of an astragalus-coptis-kudzu vine root co-extract; the biological preparation comprises the following components: recombinant human interferon alpha-2b150-200IU, 0.03-0.05 mg of an anti-PD-1 antibody fragment, 0.08-0.1 [mu] g of a brain-derived neurotrophic factor (BDNF) and 0.05-0.1 mg of a glucagon-like peptide-1 (GLP-1) analogue, and by means of multi-target linkage, traditional Chinese medicine polysaccharide synergistic protection of the biological preparation, dynamic dosage regulation and the like, the treatment effect on complex diseases is improved, and the dosage and side effects of the biological preparation are reduced.

The present invention relates to a composition for treating diabetes or obesity. In one embodiment, the present invention relates to peptide analogs of pancreatic polypeptide (PP) for use in the treatment of diabetes or obesity. Also disclosed are methods of treating diabetes or obesity, as well as the use of the peptide analogs according to the invention for the preparation of a medicament for the treatment of diabetes or obesity.

The present invention relates to insect neuropeptide compounds of the family of pyroglutamic peptides and analogs thereof having activity against insects, such as Hemiptera, Diptera, Lepidoptera, Blattaria and / or Coleoptera insects, such as aphids and fruit flies, and their use as insect control agents (e.g. insecticides) and plant protection agents.

This invention relates to isolated polypeptides that are analogs of human amylin. The disclosed amylin analog polypeptides have beneficial physicochemical properties relative to endogenous amylin, such as longer elimination half-lives (t1 / 2) and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed amylin analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed amylin analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as types 1 and 2 diabetes, and providing weight loss.

[Problem] The present invention addresses the problem of providing: a persulfide-containing composition containing a compound that is derived from a natural product or is widely used as an additive and that can stabilize a glutathione analogue persulfide or a cysteine analogue persulfide; and a method for stabilizing a persulfide. [Solution] By having a polyphenol coexist with a glutathione analogue persulfide or a cysteine analogue persulfide, it is possible to suppress degradation of the glutathione analogue persulfide or the cysteine analogue persulfide and stabilize the persulfide.

Uses of novel peptide analogs of a θ-defensin that have been developed which provide a biphasic effect in treating infection and / or sepsis are described. These analogs are active at concentrations below those needed to provide a bactericidal or bacteriostatic effect, and function by initially recruiting effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response characteristic of sepsis and septic shock. These novel θ-defensin analogs are protective at concentrations where naturally occurring θ-defensins have no apparent effect, and include a core set of structural and sequence features not found in native θ-defensin.

Disclosed are glucose-dependent insulinotropic peptide (GIP) derived peptide analogs that are antagonists of the GIP receptor. These GIP peptide analogs are modified by the inclusion of one or more individual amino acid substitutions and are conjugated to a fatty acid with / without a linker, thereby having improved antagonistic activity and improved pharmacokinetic profiles.

To provide glucose-dependent insulinotropic peptide (GIP)-derived peptide analogues which are antagonists of the GIP receptor.SOLUTION: The invention provides GIP-derived peptide analogues having specific sequences. The GIP peptide analogues are optimized by comprising amino acid substitutions A13Aib and / or N24E, and are fatty acid conjugated with / without a linker, thereby having improved solubility and / or physical stability.SELECTED DRAWING: None

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

The present invention relates to compositions for use in the treatment of diabetes or obesity. In one embodiment, the present invention relates to a peptide analogue of pancreatic polypeptide (PP) for use in the treatment of diabetes or obesity. Also disclosed are methods of treatment of diabetes or obesity, and use of a peptide analogue according to the invention in the manufacture of a medicament for treating diabetes or obesity.

The present invention discloses a polypeptide compound with anti-inflammatory activity or pharmaceutically acceptable salts thereof, wherein the polypeptide compound is screened and identified from the key residue sequences of the interaction between the two in the crystal structures of the binary complex of STING. The polypeptide compound provided by the present invention can target STING to produce anti-inflammatory effects, and can be used for the treatment of gonitis and osteoarthritis.

The present invention relates to a WKYMVm peptide analogue and uses thereof, and the WKYMVm peptide analogues have increased stability due to an increased in vivo degradation half-life, enhance activity of neutrophils as a formylpeptide receptor agonist, and regulate the activity of immune cells mediating pathology of multiple sclerosis so that they can be effectively used for enhancing immunity or preventing or treating multiple sclerosis.

A peptide or peptide analogue (P1) containing at least 5 N-terminal proteinogenic or non-proteinogenic amino acid residues of the IEX1X2V sequence, wherein: a. X1 from tyrosine (Y), serine (S) b. X2 was selected from alanine (A), aspartic acid (D).

To provide hepcidin analogs with improved in vivo half-lives, and related pharmaceutical compositions and methods of use thereof.SOLUTION: The present invention relates generally to hepcidin analog peptides and methods of making and using the same. In certain embodiments, hepcidin analogs exhibit one or more hepcidin activities. In certain embodiments, the present invention is directed to hepcidin peptide analogs comprising one or more peptide subunits, wherein the peptide subunits form a cyclized structure via an intramolecular bond, e.g., an intramolecular disulfide bond. In certain embodiments, cyclized structures have increased potency and selectivity compared to non-cyclized hepcidin peptides and analogs thereof. In certain embodiments, the hepcidin analog peptides of the present invention exhibit an extended half-life compared to hepcidin or conventional hepcidin analogs when delivered orally.SELECTED DRAWING: None

Disclosed are peptide analogs derived from glucose dependent insulinotropic peptide (GIP), which are antagonists of the GIP receptor. These GIP peptide analogs are modified by comprising one or more individual amino acid substitutions and are conjugated to fatty acids with / without linkers, thereby having improved antagonistic activity and improved pharmacokinetic profiles.

A total synthesis of a new class of vancomycin analogues of reduced synthetic complexity was developed. The synthesis, achieved by the addition of two aryl chloride substituents to provide tetrachlorovancomcyin aglycon (Compound II), tetrachlorovancomcyin (Compound I ), and their derivatives, permitted a streamlined total synthesis of the new class of glycopeptide antibiotics by removing atropisomer stereochemical control and enabled the simultaneous and further activated SNAr macrocyclizations that establish the tricyclic skeleton of Compound I. In addition to the antimicrobial evaluation of tetrachlorovancomycin (Compound I), the preparation of key binding pocket and peripherally-modi fied derivatives, which overcome vancomycin resistance and introduce independent and synergistic mechanisms of action, revealed their exceptional antimicrobial potency and provide the foundation for use of this new class of synthetic glycopeptide analogues. Also disclosed are a pharmaceutical composition containing bactericidal amount of tetrachlorovancomycin, a derivative thereof or a salt of either dissolved or dispersed in a pharmaceutically acceptable diluent.

The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and / or prevention of a variety of diseases, conditions or disorders, including treatment and / or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.

Doses and dosing regimens for incretin analogs are disclosed comprising determining and administering doses of long-acting incretin analogs suitable for once-weekly dosing, such as a glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon (GCG) (GGG) tri-receptor agonist.

Hydrochloride salt forms of synthetic C-terminal peptide analogs of C5a, which are response selective agonists of C5aR-bearing antigen presenting cells. Methods of inducing an immune response in a subject by administering such peptide analogs alone or in combination with other active agents are also disclosed.

The application discloses a RAP polypeptide analogue and medical use thereof, and belongs to the polypeptide medical field, and the amino acid sequence of the RAP polypeptide analogue is Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-Xaa17, and the N terminal of the RAP polypeptide analogue is acetylated, and the C terminal amino acid is amidated. Compared with the natural RAP polypeptide, the analogue has higher stability, bioavailability and drug efficacy, meanwhile, the dosage is low, the toxic and side effects are not obvious, the production cost is low, and the analogue has good popularization and clinical application prospects. The analogue is suitable for preventing and treating acute and chronic nephritis, chronic nephropathy and renal fibrosis caused by the acute and chronic nephritis, pulmonary inflammation and pulmonary fibrosis caused by the pulmonary inflammation, chronic liver disease and liver fibrosis caused by the chronic liver disease and the like.

The present invention relates to compounds comprising a modified W peptide analogue and optionally a conjugated moiety, and further optionally a linking group linking the modified W peptide and the conjugated moiety.